RUBY - Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter

Updating the progress of its clinical pipeline ahead of its first Pipeline and Platform Day, Rubius Therapeutics (NASDAQ:RUBY) said that additional data from its early-stage trial for off-the-shelf cellular therapy candidate RTX-240 are expected in Q1 2022. RTX-240 is undergoing a Phase 1 trial in solid tumors. Its additional results and data from a Phase 1 arm in relapsed/refractory Acute Myeloid Leukemia (AML) were expected in Q4 2021 or Q2 2022, the company said in November. However, there were no dose-limiting toxicities in the Phase 1 trial for RTX-240 in solid tumors, Rubius (RUBY) noted, adding that in Q1 2022, the candidate is set to undergo Phase 2 expansion cohorts designed to test it against select solid tumor types. As previously disclosed, the company plans to report initial Phase 1 clinical results in Q1 2022 for RTX-321 in patients with advanced HPV 16-positive cancers. Rubius (RUBY) is also on track

For further details see:

Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter